Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this study is to assess the role of sociocognitive and interpersonal factors in the therapeutic adherence of multiple sclerosis patients. This study will provide a better understanding of the socio-psychological issues associated with different types of non-adherence to treatment, and identify the risk factors and vulnerability of each patient.
Multiple sclerosis is a chronic and progressive disease that affects young adults (between 20 and 40 years old), impacting significantly the patients quality of life.
The adherence to therapy affects the long-term functional clinical course (lower risk of relapses, reduction in disability progression and quality of life). The non-adherence rate to therapy in multiple sclerosis is estimated at 40%. The main identified causes of non-adherence are: forgetting to take treatment and adverse effects of drugs.
Sociocognitive models as the Theory of Planned Behaviour (TPB) have been developed to help to understand and predict health-related behaviours. This model postulates that the intention to adopt a behaviour is one of the major determinants in the context of health. This intention comes from three independent elements :
Multiple sclerosis adherence to therapy studies have mainly focused on somatic variables (physical disability, illness duration, type of treatment) and some clinical variables (cognitive impairment, fatigue, depression). The few studies that have examined the multiple sclerosis therapeutic adherence determinants have mainly taken a one-dimensional perspective, such as perceived control.
In the FELSA-SEP study, the role of sociocognitive factors (norms and beliefs, perceived threat to disease and health behaviours) and interpersonal factors (social support, patient-doctor relationship) will be explored.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Multiple sclerosis patients | Patients with multiple sclerosis over 18 years old who have already started a long-term treatment and consent to participate to the study |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Study of the role of sociocognitive factors | Other | Questionnaires |
|
| Measure | Description | Time Frame |
|---|---|---|
| Therapeutic adherence evaluated by a Likert scale | This 19-item self-questionnaire provides 5 sub-scores corresponding to each of the sub-dimensions (Attitudes, Subjective norms, Perception of control, Behavioural intention and Behaviour) and an overall score (sum of the 5 sub-scores). | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Perceived threat measured with a self-assessment form | The perceived threat will be measured with a self-assessment form using a 5-point scale ranging from 1 (strongly disagree) to 5 (strongly agree). This 11-item self-questionnaire provides 2 sub-scores and an overall score (sum of the 2 sub-scores). | 3 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Persons with multiple sclerosis who will be recruited during a routine neurological consultation and who present eligibility criterion.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Marie-Paule Lebitasy, MD, PhD | Contact | 03.20.22.52.69 | Lebitasy.Marie-Paule@ghicl.net | |
| Lucile POISSON, PhD | Contact | 03.20.22.59.02 | poisson.lucile@ghicl.net |
| Name | Affiliation | Role |
|---|---|---|
| Bruno Lenne | Hôpital Saint Vincent de Paul, Lille | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHRU DE Bordeaux | Recruiting | Bordeaux | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| D000074822 | Treatment Adherence and Compliance |
| ID | Term |
|---|---|
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Perceived interpersonal relationships quality measure by the perceived social support questionnaire (QSSP) |
|
| 6 months |
| Perceived interpersonal relationships quality measure by the 4-Point ordinal Alliance Scale (11-items 4-PAS) | The 4-Point ordinal Alliance Scale (11-items 4-PAS). This self-questionnaire concerns the patient's feelings about the therapeutic alliance and includes eleven items, placing the patient on 5-point scale on : the patient's feeling about the doctor's ability to help him/her; his/her understanding of the symptoms of the illness; the psychological improvement felt; the adaptation to the doctor-patient relationship; the doctor's availability and competence; the clarity of the information given by the doctor and the understanding he/she shows; the doctor's desire of clinical improvement; the quality of the relationship and the understanding of psychological difficulties | 6 months |
| Illness duration in days | In order to evaluate the vulnerability and protective factors related to somatic disease illness duration will be evaluated. | 3 weeks |
| Handicap will be evaluated by the Expanded Disability Status Scale (EDSS) | In order to evaluate the vulnerability and protective factors related to somatic the handicap will be evaluated by the EDSS. The EDSS quantifies disability in eight Functional Systems (FS) by assigning a Functional System Score in each of these functional systems. The clinical meaning of each possible result goes from 0.0: Normal Neurological Exam to 10.0: Death | 3 weeks |
| Relapses number | In order to evaluate the vulnerability and protective factors related to somatic disease number of relapses will be evaluated | 3 weeks |
| Fatigue perceived through the FSS (Fatigue Severity Scale) | In order to evaluate the vulnerability and protective factors related to somatic disease fatigue will be evaluated. The items are scored on a 7 point scale with 1 = strongly disagree and 7= strongly agree. The minimum score = 9 and maximum score possible = 63. Higher the score = greater fatigue severity. | 3 weeks |
| Cognitive disorders through the SDMT (Symbol Digit Modalities Test) | In order to evaluate the vulnerability and protective factors related to somatic disease cognitive disorders will be evaluated The SDMT is a sign coding test that assesses attentional abilities (sustained attention and speed of processing information). Participants are required to use a coded key to match nine abstract symbols paired with numerical digits. The final score is the correct number of substitutions in 90 seconds, and scores range between 0 and 110. | 3 weeks |
| Anxiety-depressive symptoms measured by the Hospital Anxiety and Depression Scale (HADS) | The vulnerability and protective factors linked to psychological functioning- as Anxiety-depressive symptoms will be determined. - Personality traits: Big Five Inventory-FR questionnaire (BFI-FR) | 3 weeks |
| Personality traits measured by the Big Five Inventory-FR questionnaire (BFI-FR) | The vulnerability and protective factors linked to psychological functioning as personality traits will be determined. The Big Five personality traits is a suggested grouping for personality traits. The theory identifies five factors:
| 3 weeks |
| Hôpital Saint-Vincent de Paul | Recruiting | Lille | 59000 | France |
|
| Hôpital Saint-Philibert | Recruiting | Lomme | 59462 | France |
|
| CHRU de Strasbourg | Recruiting | Strasbourg | France |
|
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D015438 | Health Behavior |
| D001519 | Behavior |